{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:47:19Z","timestamp":1772160439504,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,10,8]],"date-time":"2007-10-08T00:00:00Z","timestamp":1191801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:bold>What is already known about this subject<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>\u2022\u2002Use of nonsteroidal anti\u2010inflammatory drugs (NSAIDs) is a strong risk and prognostic factor for peptic ulcer perforation, and alternative analgesics are needed for high\u2010risk patients.<\/jats:p>\n                    <jats:p>\u2022\u2002Pain management guidelines propose tramadol as a treatment option for mild\u2010to\u2010moderate pain in patients at high risk of gastrointestinal side\u2010effects, including peptic ulcer disease.<\/jats:p>\n                    <jats:p>\u2022\u2002Tramadol may mask symptoms of peptic ulcer complications, yet tramadol's effect on peptic ulcer prognosis is unknown.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What this study adds<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>\u2022\u2002In this population\u2010based study of 1271 patients hospitalized with peptic ulcer perforation, tramadol appeared to increase mortality at least as much as NSAIDs.<\/jats:p>\n                    <jats:p>\u2022\u2002Among users of tramadol, alone or in combination with NSAIDs, adjusted 30\u2010day mortality rate ratios were 2.02 [95% confidence interval (CI) 1.17, 3.48] and 1.32 (95% CI 0.89, 1.95), compared with patients who used neither tramadol nor NSAIDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Use of nonsteroidal anti\u2010inflammatory drugs (NSAIDs) increases risk and worsens prognosis for patients with complicated peptic ulcer disease. Therefore, patients who are at high risk of peptic ulcer often use tramadol instead of NSAIDs. Tramadol's effect on peptic ulcer prognosis is unknown. The aim was to examine mortality in the 30\u2003days following hospitalization for perforated peptic ulcer among tramadol and NSAID users compared with non\u2010users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study was based on data on reimbursed prescriptions and hospital discharge diagnoses for the 1993\u20132004 period, extracted from population\u2010based healthcare databases. All patients with a first\u2010time diagnosis of perforated peptic ulcer were identified, excluding those with previous ulcer diagnoses or antiulcer drug use. Cox regression was used to estimate 30\u2010day mortality rate ratios for tramadol and NSAID users compared with non\u2010users, adjusting for use of other drugs and comorbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1271 patients with perforated peptic ulcers included in the study, 2.4% used tramadol only, 38.9% used NSAIDs and 7.9% used both. Thirty\u2010day mortality was 28.7% overall and 48.4% among users of tramadol alone. Compared with the 645 patients who used neither tramadol nor NSAIDs, the adjusted mortality rate in the 30\u2003days following hospitalization was 2.02\u2010fold [95% confidence interval (CI) 1.17, 3.48] higher for the 31 \u2018tramadol only\u2019 users, 1.41\u2010fold (95% CI 1.12, 1.78) higher for the 495 NSAID users and 1.32\u2010fold (95% CI 0.89, 1.95) higher for the 100 patients who used both drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients hospitalized for perforated peptic ulcer, tramadol appears to increase mortality at a level comparable to NSAIDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1365-2125.2007.03038.x","type":"journal-article","created":{"date-parts":[[2007,10,8]],"date-time":"2007-10-08T07:23:13Z","timestamp":1191828193000},"page":"565-572","source":"Crossref","is-referenced-by-count":19,"title":["Perforated peptic ulcer and short\u2010term mortality among tramadol users"],"prefix":"10.1111","volume":"65","author":[{"given":"Marie L.","family":"T\u00f8rring","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Riis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reimar W.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jepsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"S\u00f8ndergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik T.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,10,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800760304"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01636772"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002689910045"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v9.i10.2338"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7046.1563"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-10-787"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00825.x"},{"key":"e_1_2_7_9_2","unstructured":"Danish Medicines Agency.Report [Consumption of strong analgesic drugs (opioids) in primary care\u2010 Denmark 1999\u20132003]. Available athttp:\/\/www.laegemiddelstyrelsen.dk\/publikationer\/netpub\/forbrugsanalyser\/opioid\/(last accessed: 18 September 2007)."},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.02.019"},{"key":"e_1_2_7_11_2","unstructured":"Recommendations for the appropriate use of opioids in persistent non\u2010cancer pain. A consensus statement prepared on behalf of the Pain Society the Royal College of Anaesthetists the Royal College of General Practitioners and the Royal College of Psychiatrists. London:The Pain Society March 2004. Available athttp:\/\/www.britishpainsociety.org\/book_opioid_main.pdf(last accessed: 18 September 2007)."},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3801(02)00143-X"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-005-0018-3"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2006.06.015"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02722.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.04.06.dc05-1748"},{"key":"e_1_2_7_18_2","first-page":"33","article-title":"[Data validity and coverage in the Danish National Health Registry. A literature review]","volume":"164","author":"Nickelsen TN","year":"2002","journal-title":"Ugeskr Laeger"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00518.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3801(02)00114-3"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200205000-00005"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0269-2813.2004.01834.x"},{"key":"e_1_2_7_23_2","first-page":"579","article-title":"A clinician's guide to the selection of NSAID therapy","volume":"27","author":"Fendrick A","year":"2002","journal-title":"Pharm Ther"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00073-4"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200006000-00028"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2007.03038.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2007.03038.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:13:24Z","timestamp":1697404404000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2007.03038.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1365-2125.2007.03038.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2007.03038.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1115170.564459","asserted-by":"object"}]},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,8]]}}}